Evidence map›Paper›PMID 37950252›Full record

Trial reportBMC urology2023

Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.

Hao Wan, Xiangpeng Zhan, Xuwen Li, Tao Chen, Xinxi Deng, Yang Liu, Jun Deng, Bin Fu, Yu Li

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hao Wan *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Xiangpeng Zhan *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Xuwen Li *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Tao Chen *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Xinxi DengDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Yang LiuDepartment of Urology, Jiu Jiang NO.1 People's Hospital, Jiujiang, Jiangxi Province, China.
Jun DengDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Bin FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Yu LiDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. 290062469@163.com.
First Affiliated Hospital of Nanchang University · CNNanchang University · CNJiujiang First People's Hospital · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

Provincial Natural Youth Fund Project 20202BAB216026
6 · The paper itself

Abstract

purposeTo investigate prognostic values of prostatic urethra involvement (PUI) and construct a prognostic model that estimates the probability of cancer-specific survival for T1 bladder cancer patients. METHOD AND MATERIALS: We investigated the national Surveillance, Epidemiology, and End Results (SEER) database (2004-2015) to get patients diagnosed with T1 bladder cancer. An external validation cohort was obtained from the First Affiliated Hospital of Nanchang University. The Kaplan-Meier method with the log-rank test was applied to assess cancer-specific survival (CSS) and overall survival (OS). Moreover, the propensity score matching (PSM) and multivariable Cox proportional hazard model were performed. All patients were randomly divided into the development cohort and validation group at the ratio of 7:3. The performance of the model was internally validated by calibration curves and the concordance index (C-index).

resultsThe PUI group had a lower survival rate of both CSS and overall survival OS before and after PSM when compared to non-involved patients (All P < 0.05). Multivariate analysis revealed a poor prognosis in the PUI group for cancer-specific mortality (CSM) and all-cause mortality (ACM) analyses before and after PSM (All P < 0.05). Seven variables, including age, surgery, radiotherapy, tumour size, PUI, and marital status, were incorporated in the final nomogram. The C-index in the development cohort was 0.715 (0.711-0.719), while it was 0.672 (0.667-0.677) in the validation group. Calibration plots for 3- and 5-year cancer-specific survival showed good concordance in the development and validation cohorts.

conclusionsPUI was an independent risk factor of ACM and CSM in T1 bladder cancer patients. In addition, a highly discriminative and precise nomogram that predicted the individualized probability of cancer-specific survival for patients with T1 bladder cancer was constructed.

Indexed as

NeoplasmsNomogramsDatabases, FactualHumansPrognosisUrethraNomogramPrognosisProstatic urethra involvedSEERT1 bladder cancer

Identifiers

PMID37950252
PMCPMC10638768
OpenAlexW4388563179

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.